- ARMP Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
Armata Pharmaceuticals (ARMP) CORRESPCorrespondence with SEC
Filed: 5 Apr 23, 12:00am
ARMATA PHARMACEUTICALS, INC.
4503 Glencoe Avenue
Marina del Rey, California 90292-3552
April 5, 2023
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Re: | Armata Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-269726) (the “Registration Statement”) |
Dear Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, the Company hereby requests that the U.S. Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on Thursday, April 6, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
If you have any questions regarding this request, please contact our outside counsel, Naveen Pogula of Thompson Hine LLP, at (404) 541-2913 or Benjamin Russell of Thompson Hine LLP, at (404) 407-3609. Please also call either Naveen Pogula or Benjamin Russell as soon as the Company’s Registration Statement on Form S-3 has been declared effective. Thank you for your attention to this matter.
Sincerely, | ||
ARMATA PHARMACEUTICALS, INC. | ||
By: | /s/ Brian Varnum | |
Name: Brian Varnum | ||
Title: Chief Executive Officer |
cc: | Naveen Pogula, Thompson Hine LLP |
Benjamin Russell, Thompson Hine LLP
Faith Charles, Thompson Hine LLP